MARKET

APRE

APRE

Aprea Therapeutics, Inc.
NASDAQ
1.054
-0.007
-0.61%
Opening 12:03 12/05 EST
OPEN
1.080
PREV CLOSE
1.060
HIGH
1.090
LOW
1.050
VOLUME
17.93K
TURNOVER
--
52 WEEK HIGH
5.00
52 WEEK LOW
0.9602
MARKET CAP
6.65M
P/E (TTM)
-0.4921
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at APRE last week (1124-1128)?
Weekly Report · 4d ago
Weekly Report: what happened at APRE last week (1117-1121)?
Weekly Report · 11/24 09:08
Weekly Report: what happened at APRE last week (1110-1114)?
Weekly Report · 11/17 09:08
Aprea Therapeutics: Promising Advancements in Synthetic Lethality Programs Drive Buy Rating
TipRanks · 11/13 16:45
Aprea Therapeutics Reports Ongoing Financial Challenges
TipRanks · 11/13 04:10
Aprea Therapeutics GAAP EPS of -$0.47, revenue of $1.84M
Seeking Alpha · 11/12 14:22
Aprea Therapeutics Reports Q3 Results and Clinical Updates
TipRanks · 11/12 13:58
Aprea Therapeutics Q3 EPS $(0.47) Misses $(0.34) Estimate, Sales $1.848K Down From $354.621K YoY
Benzinga · 11/12 13:42
More
About APRE
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. It is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. It also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.

Webull offers Aprea Therapeutics Inc stock information, including NASDAQ: APRE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APRE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APRE stock methods without spending real money on the virtual paper trading platform.